Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Grey

Showing results (241-250 of 256) with videos related to

Pageof 26
Sort By:
The New England Journal of Medicine|January 15, 2025
Fracture Prevention with Infrequent Zoledronate in Women 50 to 60 Years of AgeMark J Bolland, Zaynah Nisa, Anna Mellar, et al.
The Journal of Clinical Endocrinology and Metabolism|March 16, 2012
Effects of intravenous zoledronate on bone turnover and bone density persist for at least five years in HIV-infected menMark J Bolland, Andrew Grey, Anne M Horne, et al.
Clinical Endocrinology|November 2, 2011
Stable bone mineral density over 6 years in HIV-infected men treated with highly active antiretroviral therapy (HAART)Mark J Bolland, Andrew Grey, Anne M Horne, et al.
The Journal of Clinical Endocrinology and Metabolism|October 17, 2025
Anti-fracture efficacy of 5- or 10- yearly zoledronate in women aged 50-60y: secondary analyses of a randomized trialMark J Bolland, Zaynah Nisa, Anna Mellar, et al.
The American Journal of Clinical Nutrition|November 13, 2009
Effects of calcium supplementation on lipids, blood pressure, and body composition in healthy older men: a randomized controlled trialIan R Reid, Ruth Ames, Barbara Mason, et al.
Schizophrenia Research|December 28, 2010
The atypical anti-psychotic clozapine decreases bone mass in rats in vivoJessica L Costa, Greg Smith, Maureen Watson, et al.
American Journal of Physiology. Endocrinology and Metabolism|April 23, 2009
Actions of fibroblast growth factor-8 in bone cells in vitroJian-Ming Lin, Karen E Callon, Jun-Sheng Lin, et al.
Bone|May 10, 2011
The skeletal effects of the tyrosine kinase inhibitor nilotinibSusannah O'Sullivan, Jian-Ming Lin, Maureen Watson, et al.
The FEBS Journal|July 11, 2013
Extended treatment with selective phosphatidylinositol 3-kinase and mTOR inhibitors has effects on metabolism, growth, behaviour and bone strengthGreg C Smith, Wee-Kiat Ong, Jessica L Costa, et al.
Endocrinology|July 8, 2016
Reduced Bone Density and Cortical Bone Indices in Female Adiponectin-Knockout MiceDorit Naot, Maureen Watson, Karen E Callon, et al.
Pageof 26

Showing results (241-250 of 256) with videos related to

Sort By:
Pageof 26
The New England Journal of Medicine|January 15, 2025
Fracture Prevention with Infrequent Zoledronate in Women 50 to 60 Years of AgeMark J Bolland, Zaynah Nisa, Anna Mellar, et al.
The Journal of Clinical Endocrinology and Metabolism|March 16, 2012
Effects of intravenous zoledronate on bone turnover and bone density persist for at least five years in HIV-infected menMark J Bolland, Andrew Grey, Anne M Horne, et al.
Clinical Endocrinology|November 2, 2011
Stable bone mineral density over 6 years in HIV-infected men treated with highly active antiretroviral therapy (HAART)Mark J Bolland, Andrew Grey, Anne M Horne, et al.
The Journal of Clinical Endocrinology and Metabolism|October 17, 2025
Anti-fracture efficacy of 5- or 10- yearly zoledronate in women aged 50-60y: secondary analyses of a randomized trialMark J Bolland, Zaynah Nisa, Anna Mellar, et al.
The American Journal of Clinical Nutrition|November 13, 2009
Effects of calcium supplementation on lipids, blood pressure, and body composition in healthy older men: a randomized controlled trialIan R Reid, Ruth Ames, Barbara Mason, et al.
Schizophrenia Research|December 28, 2010
The atypical anti-psychotic clozapine decreases bone mass in rats in vivoJessica L Costa, Greg Smith, Maureen Watson, et al.
American Journal of Physiology. Endocrinology and Metabolism|April 23, 2009
Actions of fibroblast growth factor-8 in bone cells in vitroJian-Ming Lin, Karen E Callon, Jun-Sheng Lin, et al.
Bone|May 10, 2011
The skeletal effects of the tyrosine kinase inhibitor nilotinibSusannah O'Sullivan, Jian-Ming Lin, Maureen Watson, et al.
The FEBS Journal|July 11, 2013
Extended treatment with selective phosphatidylinositol 3-kinase and mTOR inhibitors has effects on metabolism, growth, behaviour and bone strengthGreg C Smith, Wee-Kiat Ong, Jessica L Costa, et al.
Endocrinology|July 8, 2016
Reduced Bone Density and Cortical Bone Indices in Female Adiponectin-Knockout MiceDorit Naot, Maureen Watson, Karen E Callon, et al.
Pageof 26